Shots:

• The collaboration will lead to evaluation of Forty Seven’s FSI-174 + magrolimab in combination with Bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform
• The focus of the collaboration is to develop gene therapy with reduced toxicity and will initially target diseases having the potential to be corrected with transplantation of autologous gene-modified blood-forming stem cells
• FSI-174 is mAb targeting cKIT while magrolimab is a mAb targeting CD47- currently being evaluated in P-II clinical study to treat cancer and other indications including myelodysplastic syndrome- acute myeloid leukemia- diffuse large B cell lymphoma and follicular lymphoma

Click here to­ read full press release/ article | Ref: Bluebird Bio | Image: Twitter